Navigation Links
Onyx Pharmaceuticals Names N. Anthony Coles, M.D. as President, Chief Executive Officer and Member of its Board of Directors
Date:2/26/2008

r was discovered, developed, approved in two indications, and successfully launched. On behalf of the company, we appreciate his vision and success commercializing this promising new cancer therapeutic."

Most recently Dr. Coles was president, chief executive officer, and a member of the board of directors of NPS Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of novel therapeutics. Before joining NPS Pharmaceuticals in 2005, Dr. Coles was senior vice president of commercial operations at Vertex Pharmaceuticals Incorporated, which he joined in 2002. Beginning in 1996, Dr. Coles held a number of executive positions while at Bristol-Myers Squibb Company, including senior vice president of strategy and policy; senior vice president of marketing and medical affairs, neuroscience/infectious diseases/dermatology; vice president, Western area sales cardiovascular and metabolic business unit for U.S. primary care; and vice president, cardiovascular global marketing. From 1992 until 1996, Dr. Coles was at Merck & Co., Inc., most recently as vice president of the hypertension and heart failure business group.

Dr. Coles earned his M.D. degree from Duke University. Subsequent to completing his internship and residency at Massachusetts General Hospital, Dr. Coles was a cardiovascular research fellow at Harvard Medical School. He also holds a master's degree in public health from Harvard University and an undergraduate degree from Johns Hopkins University. Dr. Coles currently serves as a trustee for Johns Hopkins University and Boston Medical Center, and as a director of FoldRx Pharmaceuticals, Inc.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treated(TM). The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R), a small molecule
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NPS Pharmaceuticals Announces Senior Management Changes
2. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
3. Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine
4. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
6. Nycomed US Inc. Acquires Bradley Pharmaceuticals, Inc.
7. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
8. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
9. Vion Pharmaceuticals to Implement a One-for-Ten Reverse Stock Split
10. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
11. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)...  Orexigen Therapeutics, Inc. (Nasdaq: OREX ) ... of Outstanding Issues (LOI) from the European Medicines Agency,s ... the NB32 Marketing Authorization Application (MAA). NB32 (naltrexone sustained ... candidate being evaluated for weight loss. The ... were adequately addressed by the Company based in part ...
(Date:7/30/2014)... PARK, Md. , July 30, 2014 /PRNewswire-USNewswire/ ... biological components to interrogate biology, but such devices ... biology. As such, researchers have ... for in vitro metabolic engineering to ... on a chip. New devices are envisioned to ...
(Date:7/30/2014)... July 30, 2014  AtheroNova Inc. (OTCBB: AHRO), ... development of compounds to safely regress atherosclerotic plaque ... that its partner, CardioNova, has accomplished first dosing ... with AtheroNova,s lead compound, AHRO-001.  This Phase 1b ... Phase 1 safety trial completed in February 2014, ...
(Date:7/30/2014)... NCERC at Southern Illinois University Edwardsville ... on corn stover pretreatment methods at a U.S. ... D.C. , “Arun’s selection for presentation at ... to the success of our postdoctoral fellowship program,” ... foresight and vision of SIUE and the Illinois ...
Breaking Biology Technology:Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3
... Calif., March 30 TorreyPines Therapeutics, Inc. (Nasdaq: ... District Court of the Southern District of New York ... of Axonyx Inc. ("Axonyx") against Axonyx and several of ... in 2006. The plaintiffs alleged that the defendants made ...
... March 30 BioMedical Enterprises, Inc. (BME), a rapidly ... of orthopaedic memory metal implants, announced today that it ... Sales and Marketing. BME specializes in nitinol implants ... ends together to promote bone union. The ...
... Stem Cell Trial to Show Dose-related Significant Improvement in ... Amorcyte, Inc. (Amorcyte) today announced data from its ... product for the treatment of damaged heart muscle following ... between cell dose and biologic effect. This is the ...
Cached Biology Technology:Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed 2BioMedical Enterprises, Inc. (BME) Announces the Appointment of Keith M. Peeples as Vice President, Sales and Marketing 2Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session 2Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session 3Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session 4
(Date:7/30/2014)... A team of biologists, led by Clemson University associate ... marine pest that will pave the way for novel ... bio-adhesives for medical and industrial applications. , The team,s ... examined the last larval stage of barnacles that attaches ... natural, possibly polymeric material that acts as an underwater ...
(Date:7/30/2014)... Press Limited today announced an across-the-board increase in ... The 2013 InCites Journal Citation Reports (Thomson Reuters, ... Biochemical Journal , Essays in Biochemistry , ... Reports all received increases in their Impact ... Society and published by Portland Press Limited. , ...
(Date:7/30/2014)... A professor from Wayne State University,s College of ... National Science Foundation for the project, "Nanoparticle-directed synthesis ... National Science Foundation, nanotechnology is the creation and ... novel properties and functions. A major bottleneck in ... methods that connect different functional materials into one ...
Breaking Biology News(10 mins):Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2Across-the-board Impact Factor increases for Portland Press Limited 2NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... and statistically significant improvements in clinical measures of ... the Etiology, Pathogenesis and Treatment of Parkinson's Disease ... positive interim results in patients with Parkinson's disease. ... statistically significant improvement in motor function on the ...
... discovered how a small molecule of RNA called microRNA ?a ... a key protein involved in the early development of heart ... the journal Nature, may aid scientists in their understanding of ... a heart cell, as well as offer researchers a way ...
... Paxinos and Dr Yuri Koutcherov of the Spinal Injuries ... Institute have been awarded ~$200,000 by the Christopher Reeve ... the rat spinal cord over the next two years. ... visit to Australia in 2003 and was impressed with ...
Cached Biology News:Neurologix announces positive results of gene therapy clinical trial in Parkinson's disease 2Neurologix announces positive results of gene therapy clinical trial in Parkinson's disease 3Neurologix announces positive results of gene therapy clinical trial in Parkinson's disease 4Neurologix announces positive results of gene therapy clinical trial in Parkinson's disease 5Neurologix announces positive results of gene therapy clinical trial in Parkinson's disease 6MicroRNA tweaks protein that controls early heart development 2MicroRNA tweaks protein that controls early heart development 33D Atlas Will Help Navigate The Spinal Cord 2
GFX PCR DNA,Gel Band Purif,100, 1 EA. Category: Nucleotide Sample Handling....
Full service including gene cloning, protien expression and purification of 1 liter culture....
Superior homology search software - in all the flavours of blast, with increased sensitivity and speed...
Protein 3D structure prediction, via threading. Easy to use....
Biology Products: